Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female
Histologically or cytologically 3b or 4 (metastatic) non-small cell lung cancer. Patients must meet any subcriteria as detailed in the protocol.
Age greater than or equal to 18 years old
ECOG performance status of 0 to 1
Prior diagnosis of brain metastases from NSCLC eligible provided that the brain metastases have been adequately treated, patient is neurologically stable and no new or progressive brain metastases identified.
Meets protocol requirements for specified laboratory values
Written informed consent
Appropriate use of effective contraception if of childbearing potential
Prior basal cell carcinoma or carcinoma in-situ of the cervix are eligible provided they have been treated with no evidence of disease
You may not be if
Prior chemotherapy for any stage of NSCLC
Prior surgery or radiation therapy within the last 2 weeks or incomplete recovery from prior procedures or therapy
Concurrent treatment or treatment within the last 2 years for any other malignancy
Grade 2 or greater nausea or Grade 1 or greater vomiting (despite antiemetic medication)
Medical conditions that would interfere with taking oral medications
Patients with bone metastases as the only site of disease
Pregnant or nursing women
Known HIV positivity or AIDS-related illness
Patients with significant QTc prolongation at baseline
Clareo Health | Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)
